Percutaneous Coronary Intervention before or after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis Involving 1531 Patients
暂无分享,去创建一个
A. Ielasi | M. Barbanti | G. Vetta | C. Montonati | A. Parlavecchio | Gianpiero Vizzari | Manuela Ajello | Dario Pellegrini | Gabriele Carciotto | Fabrizio Ceresa | A. Micari | F. Patané | D. D. Della Rocca | Giulia Laterra | Rodolfo Caminiti | Mariano Pellicano | N. Mancini | Giustina Iuvara | Francesco Costa
[1] A. Ielasi,et al. Technical Aspects for Transcatheter Aortic Valve Replacement With the Novel Balloon-Expandable Myval Octacor. , 2024, JACC. Cardiovascular interventions.
[2] F. Burzotta,et al. Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation. , 2023, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] P. Teirstein,et al. Three-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis. , 2023, Journal of the American College of Cardiology.
[4] Samin K. Sharma,et al. Improved Commissural Alignment in TAVR With the Newest Evolut FX Self-Expanding Supra-Annular Valve: First-in-Human Experience. , 2022, JACC. Cardiovascular interventions.
[5] T. Engstrøm,et al. Long-term changes in coronary physiology after aortic valve replacement. , 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[6] A. Ielasi,et al. Minimalistic contrast-zero aortic valve-in-valve replacement using the novel Hydra trans-catheter valve in a patient with severe chronic kidney disease. , 2022, Cardiovascular revascularization medicine : including molecular interventions.
[7] F. Ribichini,et al. Optimal timing for percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation. , 2022, International journal of cardiology.
[8] H. Thiele,et al. Bleeding risk differences after TAVR according to the ARC-HBR criteria: insights from SCOPE 2. , 2022, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[9] A. Baumbach,et al. Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. , 2021, JACC. Cardiovascular interventions.
[10] A. Zaman,et al. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial. , 2021, JACC. Cardiovascular interventions.
[11] B. Prendergast,et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.
[12] D. Steinbrüchel,et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement , 2021, European heart journal.
[13] M. Leon,et al. Coronary Cannulation After Transcatheter Aortic Valve Replacement: The RE-ACCESS Study. , 2020, JACC. Cardiovascular interventions.
[14] P. Stella,et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. , 2020, The New England journal of medicine.
[15] Jeroen J. Bax,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.
[16] K. Gould,et al. Coronary Microcirculation in Aortic Stenosis: Pathophysiology, Invasive Assessment, and Future Directions , 2020, Journal of interventional cardiology.
[17] R. Makkar,et al. Coronary Access After TAVR. , 2020, JACC. Cardiovascular interventions.
[18] R. Makkar,et al. Timing and Outcomes of Percutaneous Coronary Intervention in Patients Who Underwent Transcatheter Aortic Valve Implantation. , 2020, The American journal of cardiology.
[19] P. Serruys,et al. Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses , 2019, Circulation. Cardiovascular interventions.
[20] C. Vassanelli,et al. Functional Assessment of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation: Influence of Pressure Overload on the Evaluation of Lesions Severity , 2016, Circulation. Cardiovascular interventions.
[21] J. Davies,et al. Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI , 2016, Nature Reviews Cardiology.
[22] Jiming Liu,et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.
[23] P. Wenaweser,et al. Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[24] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[25] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.